Sort publications on year
-
Biometry and database analysis
Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study
GIRARD N, MORO-SIBILOT D, BOUEE S, EMERY C, TORRETON E, LE LAY K, LUCIANI L, MARITAZ C, CHOUAID C
Future Oncol ; 2020;16(16),1115-1124
-
Pharmaco-Economics
Absenteeism and indirect costs during the year following the diagnosis of an operable breast cancer: A prospective multicentric cohort study
FERRIER C, THEBAUT C, BAFFERT S, ASSELAIN B, ROUZIER R,HEQUET D
J Gynecol Obstet Hum Reprod ; 2020(Online)
-
Biometry and database analysis
Effectiveness of sequencing TKIs in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC): A French national medical-administrative claim database analysis
GIRARD N, BOUEE S, MORO-SIBILOT D, EMERY C, LE LAY K, LUCIANI L, MARITAZ C, CHOUAID C
Annals of Oncology ; 2019;30(5):v627-v628
-
Pharmaco - Epidemiology
Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study
GIRARD N, MORO-SIBILOT D, BOUEE S, EMERY C, TORRETON E, LE LAY K, LUCIANI L, MARITAZ C, CHOUAID C.
Future Oncol ; 2020;16(16),1115-1124
-
Pharmaco-Economics
Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study
HEQUET D, HUCHON C, SOILLY AL, ASSELAIN B, BERSENEFF H, TRICHOT C, COMBES A, ALVES K, NGUYEN T, ROUZIER R, BAFFERT S.
PLoS One ; 2019;14(7)
-
Biometry and database analysis
Economic burden of chemotherapy-treated recurrent and/or metastatic squamous cell carcinoma of the head and neck in france: real world data from the permanent sample of national health insurance beneficiairies.
LAFUMA A, COTTÉ FE, LE TOURNEAU C, EMERY C, GAUDIN AF, TORRETON E, GOURMELEN J, BONASTRE J.
J Med Econ ; 2019
-
Pharmaco-Economics
Cost-effectiveness of web-based patient-reported outcome surveillance in lung cancer patients.
LIZÉE T, BASCH E, TRÉMOLIÈRES P, VOOG E, DOMONT J, PEYRAGA G, URBAN T, BENNOUNA J, SEPTANS A-L, BALAVOINE M, DETOURNAY B, DENIS F.
J Thorac Oncol ; 2019;14(6):1012-1020
-
Pharmaco-Economics
Determinants of return at work of breast cancer patients: results from the OPTISOINS01 French prospective study
ARFI A, BAFFERT S, SOILLY AL, HUCHON C, REYAL F, ASSELAIN B, NEFFATI S, ROUZIER R, HÉQUET D.
BMJ Open ; 2018;8(5):e020276
-
Public Health and Epidemiology
Un outil de suivi et d’auto-évaluation du bon usage du médicament en cancérologie : l’observatoire du médicament d la FNCLCC
LATOUR JF, GAMEROFF S, GENEVE J, FAGNANI F
J Pharm Clin ; 26(3):151-157
-
Pharmaco-Economics
Evaluation économique du trastuzumab en traitement adjuvant du cancer du sein précoce surexprimant HER2
FAGNANI F, COLIN X, ARVEUX P, COUDERT B, MISSET JL
Bulletin du Cancer ; 94(7):711-720
-
Pharmaco-Economics
Invasive cervical cancer treatment costs in France
ARVEUX P, BENARD S, BOUEE S, LAFUMA A, MARTIN L, CRAVELLO L, REMY V, BREUGELMANS JG
Bull Cancer ; 94(2):219-224
-
Pharmaco-Economics
Coût de la prise en charge des frottis anormaux et des néoplasies intraépithéliales du col de l’utérus en France
BERGERON C, COHET C, BOUEE S, LORANS C, REMY V
BEH ; (1):4-6
-
Pharmaco-Economics
Cost Consequences of Adjuvant Capecitabine, Mayo Clinic and de Gramont Regimens for Stage III Colon Cancer in the French Setting
DOUILLARD JY, TILLEUL P,YCHOU M, DUFOUR P, PERROCHEAU G, SEITZ JF, MAES P, LAFUMA A, HUSSEINI F
Oncology ; 72:248-254
-
Pharmaco-Economics
Cervical cancer screening and associated treatment costs in France
BERGERON C, BREUGELMANS JG, BOUEE S, LORANS C, BENARD S, REMY V
Gynécol Obstét Fertil ; 34:1036-1042
-
Public Health and Epidemiology
Le dépistage du cancer du sein en France : bilan et limites
PHILIP T, KASPARIAN C, FAGNANI F,MOATTI JP, MEUNIER A
Bull. Acad. Natle Méd. ; 189(2):321-339
